284 related articles for article (PubMed ID: 30084057)
1. Resistance detection and re-treatment options in hepatitis C virus-related chronic liver diseases after DAA-treatment failure.
Sagnelli E; Starace M; Minichini C; Pisaturo M; Macera M; Sagnelli C; Coppola N
Infection; 2018 Dec; 46(6):761-783. PubMed ID: 30084057
[TBL] [Abstract][Full Text] [Related]
2. Clinical impact of the hepatitis C virus mutations in the era of directly acting antivirals.
Coppola N; Minichini C; Starace M; Sagnelli C; Sagnelli E
J Med Virol; 2016 Oct; 88(10):1659-71. PubMed ID: 26991255
[TBL] [Abstract][Full Text] [Related]
3. Resistance Associated Mutations in HCV Patients Failing DAA Treatment.
Di Stefano M; Faleo G; Farhan Mohamed AM; Morella S; Bruno SR; Tundo P; Fiore JR; Santantonio TA
New Microbiol; 2021 Jan; 44(1):12-18. PubMed ID: 33453702
[TBL] [Abstract][Full Text] [Related]
4. Direct acting antivirals failure: cause and retreatment options.
Parlati L; Pol S
Expert Rev Gastroenterol Hepatol; 2018 Dec; 12(12):1245-1250. PubMed ID: 30791789
[TBL] [Abstract][Full Text] [Related]
5. [RESISTANCE OF HCV TO NEW DIRECT ACTING ANTIVIRALS].
Gozlan Y; Mendelson E; Ben-Ari Z; Mor O
Harefuah; 2015 Nov; 154(11):684-7, 743. PubMed ID: 26821497
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis C virus resistance to the new direct-acting antivirals.
Esposito I; Trinks J; Soriano V
Expert Opin Drug Metab Toxicol; 2016 Oct; 12(10):1197-209. PubMed ID: 27384079
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis C virus early kinetics and resistance-associated substitution dynamics during antiviral therapy with direct-acting antivirals.
Perpiñán E; Caro-Pérez N; García-González N; Gregori J; González P; Bartres C; Soria ME; Perales C; Lens S; Mariño Z; Londoño MC; Ariza X; Koutsoudakis G; Quer J; González-Candelas F; Forns X; Pérez-Del-Pulgar S
J Viral Hepat; 2018 Dec; 25(12):1515-1525. PubMed ID: 30141252
[TBL] [Abstract][Full Text] [Related]
8. Impact of hepatitis C virus polymorphisms on direct-acting antiviral treatment efficacy: Regulatory analyses and perspectives.
Harrington PR; Komatsu TE; Deming DJ; Donaldson EF; O'Rear JJ; Naeger LK
Hepatology; 2018 Jun; 67(6):2430-2448. PubMed ID: 29194682
[TBL] [Abstract][Full Text] [Related]
9. Evolution of multi-drug resistant HCV clones from pre-existing resistant-associated variants during direct-acting antiviral therapy determined by third-generation sequencing.
Takeda H; Ueda Y; Inuzuka T; Yamashita Y; Osaki Y; Nasu A; Umeda M; Takemura R; Seno H; Sekine A; Marusawa H
Sci Rep; 2017 Mar; 7():45605. PubMed ID: 28361915
[TBL] [Abstract][Full Text] [Related]
10. Future treatment of chronic hepatitis C with direct acting antivirals: is resistance important?
Halfon P; Sarrazin C
Liver Int; 2012 Feb; 32 Suppl 1():79-87. PubMed ID: 22212577
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis C virus resistance to protease inhibitors.
Halfon P; Locarnini S
J Hepatol; 2011 Jul; 55(1):192-206. PubMed ID: 21284949
[TBL] [Abstract][Full Text] [Related]
12. Antiviral resistance and direct-acting antiviral agents for HCV.
Aloia AL; Locarnini S; Beard MR
Antivir Ther; 2012; 17(6 Pt B):1147-62. PubMed ID: 23188771
[TBL] [Abstract][Full Text] [Related]
13. Excellent outcome of direct antiviral treatment for chronic hepatitis C in Switzerland.
Bachofner J; Valli PV; Bergamin I; Kröger A; Künzler P; Baserga A; Braun DL; Seifert B; Moncsek A; Fehr J; Semela D; Magenta L; Müllhaupt B; Terziroli Beretta-Piccoli B; Mertens J; The Swiss Hepatitis C Cohort Study
Swiss Med Wkly; 2018; 148():w14560. PubMed ID: 29376557
[TBL] [Abstract][Full Text] [Related]
14. The role of resistance in HCV treatment.
Vermehren J; Sarrazin C
Best Pract Res Clin Gastroenterol; 2012 Aug; 26(4):487-503. PubMed ID: 23199507
[TBL] [Abstract][Full Text] [Related]
15. [A new challenge in clinical practice: resistance to directly acting antivirals in hepatitis C treatment].
Chen ZW; Hu P; Ren H
Zhonghua Gan Zang Bing Za Zhi; 2016 Mar; 24(3):165-9. PubMed ID: 27095757
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis C virus markers in infection by hepatitis C virus: In the era of directly acting antivirals.
Coppola N; Pisaturo M; Zampino R; Macera M; Sagnelli C; Sagnelli E
World J Gastroenterol; 2015 Oct; 21(38):10749-59. PubMed ID: 26478667
[TBL] [Abstract][Full Text] [Related]
17. Geno2pheno[HCV] - A Web-based Interpretation System to Support Hepatitis C Treatment Decisions in the Era of Direct-Acting Antiviral Agents.
Kalaghatgi P; Sikorski AM; Knops E; Rupp D; Sierra S; Heger E; Neumann-Fraune M; Beggel B; Walker A; Timm J; Walter H; Obermeier M; Kaiser R; Bartenschlager R; Lengauer T
PLoS One; 2016; 11(5):e0155869. PubMed ID: 27196673
[TBL] [Abstract][Full Text] [Related]
18. The importance of resistance to direct antiviral drugs in HCV infection in clinical practice.
Sarrazin C
J Hepatol; 2016 Feb; 64(2):486-504. PubMed ID: 26409317
[TBL] [Abstract][Full Text] [Related]
19. Directly acting antivirals against hepatitis C virus: mechanisms of action and impact of resistant associated variants.
Premoli C; Aghemo A
Minerva Gastroenterol Dietol; 2016 Mar; 62(1):76-87. PubMed ID: 26448306
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of antiviral effect of type I, II, and III interferons on direct-acting antiviral-resistant hepatitis C virus.
Hamana A; Takahashi Y; Uchida T; Nishikawa M; Imamura M; Chayama K; Takakura Y
Antiviral Res; 2017 Oct; 146():130-138. PubMed ID: 28864074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
